V enous thromboembolism leading to pulmonary embolism is a potentially life-threatening complication in orthopedic and trauma surgery. The effectiveness of thromboprophylaxis in reducing thromboembolic events in patients undergoing major fracture surgery is well documented.
1 Subcutaneous injection of low-molecular-weight heparin or other antithrombotic agents is the standard of care. 1 Oral thromboprophylactic agents may offer considerable advan-abstract This study investigated the effectiveness and the outcomes of rivaroxaban vs the standard of care for venous thromboembolic prophylaxis in patients undergoing fracture-related surgery. A total of 413 patients undergoing fracture-related surgery from 9 Swiss orthopedic and trauma centers were enrolled. The authors selected the type of venous thromboembolic prophylaxis according to standardized medical practice at the participating centers before the inclusion of patients: 208 patients received rivaroxaban and 205 received the standard of care. Data on symptomatic thromboembolic and bleeding events, surgery-related complications, death, adverse events, time to mobilization, and hospital discharge were collected. Symptomatic thromboembolic events were reported in 1 patient (0.5%) and 2 patients (1.0%) and treatment-emergent major bleeding events were reported in 1 patient (0.5%) and 2 patients (1.0%) receiving rivaroxaban and the standard of care, respectively. The durations of hospital stay and venous thromboembolic prophylaxis were similar in the 2 groups. In both groups, adverse events related to venous thromboembolic prophylaxis were reported in 12 patients. The proportion of patients with minor and major fracture surgery was 74.3% and 25.7%, respectively. In patients undergoing minor fracture surgery receiving rivaroxaban (n=167) and the standard of care (n=140), no symptomatic thromboembolic events and no major bleeding events were reported. Outcomes of this study indicate that rivaroxaban might be an appropriate oral alternative for venous thromboembolic prophylaxis in routine medical care after fracture-related major and minor surgery. Reported results were comparable to those from other large-scale, noninterventional and randomized controlled studies. [Orthopedics. 2017; 40(2):109-116.] tages, particularly for prolonged ambulatory thromboprophylaxis after hospital discharge. 2, 3 Complications of thromboprophylaxis, including bleeding events, have been reported and may cause concern. In addition, patient compliance with selfadministration of a subcutaneous injection may be a problem in some cases.
In randomized controlled studies, rivaroxaban, an oral direct Xa inhibitor that is administered once daily, showed superior efficacy and a similar safety profile compared with enoxaparin for patients undergoing elective hip or knee surgery. [4] [5] [6] [7] [8] Results of the RECORD 1 to 3 study [4] [5] [6] 8 showed major bleeding events in 0.3% and 0.2% of patients treated with rivaroxaban and enoxaparin, respectively. 2 There is a need to evaluate the effectiveness and safety of any novel anticoagulant used in routine medical care.
9
Randomized clinical trials apply stringent eligibility criteria and interventional procedures for treatment. Real-world outcomes of a multinational noninterventional study of 17,701 patients (XAMOS study 9, 10 ) comparing rivaroxaban with the standard of care were reported. The incidence of symptomatic thromboembolic events was 0.9% and 1.4% in patients receiving rivaroxaban and the standard of care, respectively. Treatment-emergent major bleeding events (RECORD definition 4 ) were reported in 0.4% and 0.3% of patients receiving rivaroxaban and the standard of care, respectively, 9,10 and these findings confirmed the favorable riskbenefit profile of rivaroxaban reported in randomized clinical trials. [4] [5] [6] [7] [8] Analysis of this nonrandomized study in unselected patients was performed with statistical methods to compensate for potential patient selection bias.
9,12
The current study reports the results of the Swiss population included in the international XAMOS study and presents the outcomes of subgroup analysis of major (hip/femur) and minor lower limb (tibia, fibula, ankle, and foot) fracture surgery.
Materials and Methods

Study Design
The noninterventional, observational XAMOS 9,10 study was conducted in 37 countries and included 17,701 patients undergoing elective or nonelective orthopedic surgery. The study was registered with Clinical Trials.gov (NCT00831714). Patients with fracture-related surgery treated at 9 Swiss orthopedic and trauma centers represent a subpopulation of this international study and were analyzed and reported separately. Independent ethics committees approved the study according to Swiss regulations. Inclusion criteria were age 13 older than 18 years, fracture-related surgery of the hip/femur or lower limb (tibia, fibula, ankle, and foot), prescribed pharmacologic prophylaxis of thromboembolic events, and signed informed consent. Exclusion criteria were according to approved local product information.
Patients
The first patient was enrolled in May 2010, and the last was enrolled in February 2012. Treatment for prophylaxis of thromboembolic events was assigned for each patient on hospitalization by the principal investigators (all of whom are authors of this article) or surgeons according to standardized medical practice and/or center-specific procedures. Patients were informed about the study after selection of the drug to be administered for prophylaxis of thromboembolic events, and all patients who were willing to participate were included in the study. This model of nonconsecutive inclusion without randomization was applied according to published noninterventional study procedures for unselected patient populations receiving routine medical care.
9, 12 The goal of this procedure was to achieve similar proportions of patients treated with rivaroxaban and the standard of care. Duration and dose of prophylaxis of thromboembolic events were at the discretion of the treating physician and according to center-specific practice.
Patient demographics, medical history, previous treatment, surgical procedures, time between hospital admission and start of surgery, preoperative treatment, type of surgery (hip/femur vs lower limb and unilateral vs bilateral), and type and duration of anesthesia and surgery were recorded. Clinical efficacy (symptomatic thromboembolic events and major bleeding events, both reported as adverse events), mortality, concomitant treatment (WHO Drug Dictionary 13 ), and clinical safety (all adverse events, MedDRA-coded 14 ) were reported. In addition, time to mobilization after surgery, time to discharge after mobilization, overall length of hospitalization, and patient location after discharge were collected.
Statistical Analysis
All patients who were enrolled and underwent surgery were included in the analysis (n=413). Demographics, medical history, surgical procedures, clinical efficacy and safety, time to mobilization after surgery, time to discharge after mobilization, and overall length of hospitalization were analyzed with descriptive statistics and presented in summary tables or frequency listings. Patients with hip/femur and lower limb (tibia, fibula, ankle, and foot) fractures also were analyzed as subgroups.
results
The current study included 9 Swiss orthopedic and trauma centers, with a total of 413 patients who underwent nonelective surgery for trauma. At 8 of the 9 centers (403 of 413 included patients), 35% to 65% of patients were treated with rivaroxaban vs the standard of care. At the remaining center (10 of 413 included patients), 80% of patients received the standard of care and 20% received rivaroxaban. In total, 208 (50.4%) patients were treated with rivaroxaban and 205 (49.6%) were treated with the standard of care. A total of 175 (84.1%) patients treated with rivaroxaban and 182 (86.4%) treated with the standard of care completed the study. Premature termination occurred among 24 (11.5%) patients treated with rivaroxaban and 20 (9.8%) patients treated with the standard of care. Premature termination occurred for the following reasons: investigator decision (rivaroxaban, 5; standard of care, 9); patient belief that the study drug was inappropriate (rivaroxaban, 8; standard of care, 1); adverse n Feature Article event (rivaroxaban, 2; standard of care, 4); supply issues related to the health system (rivaroxaban, 5; standard of care, 1); patient belief that the study drug was inconvenient (rivaroxaban, 2; standard of care, 2); and unknown (rivaroxaban, 2; standard of care, 3). Follow-up information was missing for 9 (4.3%) patients in the rivaroxaban group and 3 (1.5%) patients in the standard of care group. Demographics, medical history, and previous treatments are presented in Table 1. Median age of patients treated with rivaroxaban and the standard of care was 50 and 54 years, respectively. Age range (rivaroxaban, 18-94 years; standard of care, 18-98 years) and proportion of patients younger than 65 years and 65 years or older (rivaroxaban, 74.0% and 26.0%, respectively; standard of care, 67.8% and 32.2%, respectively) were similar in the 2 treatment groups.
The proportions of patients with medical history findings according to Med-DRA in the rivaroxaban and the standard of care groups were comparable overall (25.5% and 29.3%, respectively). Preoperative use of heparin (at least 1 dose within 7 days before surgery) was reported in 92 (44.2%) and 7 (3.4%) of patients treated with rivaroxaban and the standard of care, respectively. Drugs with potential interactions in combination with antithrombotic treatment, such as CYP3A4 inhibitors/inducers, P-gp inhibitors/inducers, platelet aggregation inhibitors, vitamin K antagonists, and antithrombotic enzymes, were rarely used (<2% of patients) preoperatively in both treatment groups. However, 207 of 208 patients treated with rivaroxaban used nonsteroidal antiinflammatory drugs (NSAIDs) before hospitalization (52.5%) and preoperatively (46.6%), and all patients treated with the standard of care used NSAIDs before hospitalization (13.2%) and preoperatively (86.8%).
Surgical procedures are summarized in Table 2 . The proportion of major fracturerelated surgical procedures (hip/femur) was lower in the rivaroxaban group (19.7%) than in the standard of care group (31.7%). Duration of surgery and duration of anesthesia were similar. Surgery-related complications were observed in 3 (1.4%) patients and 4 (2.0%) patients treated with rivaroxaban and the standard of care, respectively.
Time to first dose and duration of prophylaxis of thromboembolic events were similar in both groups. Daily doses in the 2 treatment groups were according to the recommended doses of the administered drugs (rivaroxaban or low-molecularweight heparin). Of patients treated with the standard of care, 187 (91.2%) used low-molecular-weight heparin at a median dose of 4000 IU (range, 2000-7500 IU). A similar rate of at least 1 concomitant treatment was reported in patients treated with rivaroxaban (94.2%) and the standard of care (97.6%). Concomitant use of drugs with potential interactions with antithrombotic treatment were rare (≤2%) in both treatment groups, except NSAIDs, which were used in the rivaroxaban and the standard of care groups regularly in 21 (10.1%) and 44 (21.5%) patients and rarely in 60 (28.8%) and 79 (38.5%) patients, respectively.
Symptomatic thromboembolic events occurred in 1 (0.5%) patient who was treated with rivaroxaban and 2 (1.0%) patients who were treated with the standard of care, and treatment-emergent bleeding events were reported in 6 (2.9%) and 7 (3.4%) patients, respectively ( Table 3) . Table 3 shows the incidence of major bleeding events, according to European Medicines Agency guidelines 11 and the RECORD definition. 4 The proportion of patients discharged home from the hospital was higher among those treated with rivaroxaban (67.8%) compared with those treated with the standard of care (58.8%) ( Table 3 ). The proportion of patients admitted to inpatient rehabilitation centers was higher among patients treated with the standard of care (31.2%) relative to patients treated with rivaroxaban (16.3%).
Lower rates of treatment-emergent adverse events and serious treatmentemergent adverse events occurred among patients treated with rivaroxaban (21.2% and 3.8%, respectively) compared with those treated with the standard of care (31.7% and 11.2%, respectively) ( Table 4) .
In each treatment group, 12 patients had treatment-emergent adverse events related to prophylaxis of thromboembolic events. Serious treatment-emergent adverse events occurred in 1 (0.5%) patient treated with rivaroxaban and 3 (1.5%) patients treated with the standard of care. In patients with hip/femur surgery who were treated with the standard of care, 2 deaths occurred. Of the patients who died, 1 (85 years old) had pneumonia that was unrelated to the standard of care or the study procedures. The other (75 years old) had concomitant anemia, hepatitis B, and a history of splenic lymphoma with villous lymphocytes, and death of unknown cause was recorded.
Results of subgroup analysis of major (hip/femur) and minor (tibia, fibula, ankle, and foot) fracture-related surgical procedures are shown in Table 5 . In both treatment groups, patients undergoing minor surgery were younger than patients undergoing major surgery. In addition, a higher proportion of men underwent minor surgery.
discussion
This noninterventional study included patients with major and minor fracturerelated surgery treated at Swiss orthopedic and trauma centers. 9 The study population represents a real-world sample of patients that is similar to the population of the global XAMOS study.
9,10
Findings for the Swiss population of patients with symptomatic thromboembolic events and treatment-emergent major bleeding events were similar to results of the noninterventional XAMOS study of elective surgery conducted in 17,701 patients 9,10 and the results of randomized controlled studies in elective hip or knee arthroplasty (RECORD). [4] [5] [6] [7] [8] The rate of patients with medication use before hospitalization and preoperatively was high and varied in the 2 treatment groups, probably reflecting individual medical histories and center-specific prophylactic protocols in routine medical care as well as individual treatment regimens for prophylaxis before surgery to treat trauma and/or to reduce pain.
The median duration of venous thromboembolic prophylaxis after discharge from the hospital was similar between patients treated with rivaroxaban and those treated with the standard of care; however, the maximal duration of venous thromboembolic prophylaxis was markedly longer in the standard of care group than in the rivaroxaban group. This finding might be explained by the postoperative course of mobilization and rehabilitation, requiring individual regimens and duration of prophylaxis. The ease and safety of ambulatory treatment after discharge reflects a key advantage of oral prophylaxis of thromboembolic events.
The proportion of patients with major (hip/femur) and minor (tibia, fibula, ankle, or foot) fracture-related surgery was slightly different in the 2 groups. The higher proportion of lower limb surgery in the rivaroxaban group and the higher proportion of hip/femur surgery in the standard of care group most likely reflect case-by-case decisions based on routine practice at the 9 centers.
A lower overall incidence of treatment-emergent adverse events related to prophylaxis of thromboembolic events Table 4 Treatment-Emergent Adverse Events in patients treated with rivaroxaban compared with the standard of care reflects the good tolerability profile of rivaroxaban and is consistent with the findings of other clinical studies. [4] [5] [6] [7] [8] [9] [10] No patient in the rivaroxaban group who had bleeding required a reversal agent. Of patients treated with rivaroxaban, those who underwent minor surgery had no symptomatic thromboembolic events, a low incidence of bleeding events, and a low rate of discontinuation of prophylaxis as a result of serious treatment-emergent adverse events. This finding indicated that rivaroxaban is a reasonable alternative to the standard of care for patients undergoing minor surgery.
Limitations
The limitations of this observational study are related to the noninterventional design and lack of randomization or stratification. The type of prophylaxis of thromboembolic events was allocated according to the common practice in each participating center before patients were asked to participate in the study. Although the overall proportion of patients assigned to rivaroxaban or the standard of care was equal and demographic features in the 2 treatment groups were similar, some other findings, such as previous and concomitant treatments, previous and preoperative use of NSAIDs, and preoperative use of heparin were unequal, most likely reflecting center-specific procedures and a possible selection bias for prophylaxis of thromboembolic events. Therefore, this analysis reveals treatment outcomes for rivaroxaban and standard of care venous thromboembolic prophylaxis in routine medical care and is not intended for comparative statistical testing. In addition, the sample size was relatively small compared with the XAMOS study, 10 particularly for analysis of major and minor fracturerelated surgery. Further controlled studies with a larger sample are required to confirm these findings.
conclusion
This study, conducted at 9 Swiss orthopedic and trauma centers, reported outcomes for patients with fracture-related surgery treated with rivaroxaban, a novel oral anticoagulant. The outcomes of this Swiss observational study were comparable to the results of a large-scale, noninterventional, randomized controlled study and showed that rivaroxaban may be an appropriate oral alternative for prophylaxis of thromboembolic events in routine care after major or minor fracture-related surgery. 
